CytomX Therapeutics (CTMX) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 1 year price objectives for CytomX Therapeutics' stock. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they predict the company's share price to reach $3.17 in the next year. This suggests a possible upside of 82.3% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.

CytomX Therapeutics' stock was trading at $1.60 at the beginning of 2023. Since then, CTMX stock has increased by 8.7% and is now trading at $1.74.
View the best growth stocks for 2023 here.

CytomX Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,130,000 shares, a decline of 13.4% from the April 30th total of 2,460,000 shares. Based on an average daily trading volume, of 758,700 shares, the short-interest ratio is presently 2.8 days. Currently, 3.3% of the shares of the company are short sold.
View CytomX Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CTMX earnings forecast.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Monday, March, 27th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.21. The biotechnology company had revenue of $0.95 million for the quarter, compared to the consensus estimate of $17.71 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 666.28% and a negative net margin of 132.29%.

ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH) and Invesco Nasdaq Future Gen 200 ETF (QQQS).

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.69%), Renaissance Technologies LLC (1.28%), FMR LLC (1.06%), Assenagon Asset Management S.A. (1.01%), Geode Capital Management LLC (0.97%) and Two Sigma Advisers LP (0.78%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $1.74.

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $115.43 million and generates $67.62 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

The company employs 174 workers across the globe.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.